Arcadia Biosciences, Inc.
RKDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,302 | $1,455 | $1,200 | $1,216 |
| % Growth | -10.5% | 21.3% | -1.3% | – |
| Cost of Goods Sold | $884 | $824 | $682 | $827 |
| Gross Profit | $418 | $631 | $518 | $389 |
| % Margin | 32.1% | 43.4% | 43.2% | 32% |
| R&D Expenses | $0 | $9 | $0 | $13 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,570 | $2,123 | $1,738 | $2,655 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1,000 | -$1,750 | $0 |
| Operating Expenses | $1,570 | $1,132 | -$12 | $2,668 |
| Operating Income | -$1,152 | -$501 | $530 | -$2,279 |
| % Margin | -88.5% | -34.4% | 44.2% | -187.4% |
| Other Income/Exp. Net | $2,008 | -$3,957 | $2,069 | -$1,750 |
| Pre-Tax Income | $856 | -$4,458 | $2,599 | -$4,029 |
| Tax Expense | $0 | $0 | $0 | $8 |
| Net Income | $856 | -$4,458 | $2,599 | -$4,064 |
| % Margin | 65.7% | -306.4% | 216.6% | -334.2% |
| EPS | 0.62 | -3.26 | 1.9 | -1.18 |
| % Growth | 119% | -271.6% | 261% | – |
| EPS Diluted | 0.62 | -3.26 | 1.9 | -1.18 |
| Weighted Avg Shares Out | 1,367 | 1,367 | 1,366 | 1,364 |
| Weighted Avg Shares Out Dil | 1,372 | 1,367 | 1,366 | 1,364 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $9 | $207 | $354 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $15 | $13 | $21 |
| EBITDA | $858 | -$1,486 | -$1,207 | -$2,258 |
| % Margin | 65.9% | -102.1% | -100.6% | -185.7% |